A booster dose of a SARS-CoV-2 vaccine cut infection risk nearly in half, study finds.
People with systemic lupus erythematosus (SLE) who get a booster dose of a SARS-CoV-2 vaccine have a significantly lower risk of breakthrough COVID-19 infections, according to a new report published online today in The Lancet Rheumatology.
This report found the rate of breakthrough infections among people with SLE who did not receive a booster shot was nearly double that seen among people with SLE who were boosted.
“Our study results offer people living with SLE clinical confirmation that vaccines are highly effective at guarding against severe COVID-19, despite their increased risk of catching the disease,” said co–lead investigator and rheumatologist Amit Saxena, MD, MS, of the New York University (NYU) Grossman School of Medicine, in a statement.
People with SLE are at a higher risk from COVID-19, the authors explained, likely due to immunologic perturbations associated with the disease and the common use of immunosuppressant medications by patients. Previous research has shown people with SLE are more likely to have severe COVID-19, be hospitalized, require mechanical ventilation, experience thrombosis, and die. Those statistics have made COVID-19 vaccination a key issue for people with SLE, both because an effective vaccine could have meaningful health benefits and because of concerns that the vaccines might not work as well in this population.
In the new study, the investigators recruited 163 fully vaccinated patients receiving treatment for SLE at NYU-affiliated hospitals. Half of the patients were taking at least 1 immunosuppressant at the time of the study; 16% were on multiple immunosuppressants.
The investigators wanted to know whether a booster shot would have a long-term impact on the risk of infection in this patient population. They evaluated patients 6 months following their initial dose, with follow-up beginning on or after February 4 of this year. Most of the patients (125 patients; 76.7%) had received a booster shot in addition to their initial course.
By the end of the monitoring period in late April, 44 patients had experienced breakthrough infections: 28 of the 125 patients (22%) who had received a booster shot and 16 of the 38 patients (42%) who did not get boosted. Only 2 of the 44 patients in the study were hospitalized because of their infection; both recovered. The authors noted that all but 2 of the breakthrough cases in the study occurred after December 2, 2021, when the first Omicron-variant case of COVID-19 was reported in New York.
The investigators also completed serologic testing of 57 patients. Those tests revealed that patients with the booster shot had significantly higher levels of SARS-CoV-2 antibodies (median of 1036 U/mL after the booster shot vs 397 U/mL after the initial vaccine series). However, the authors did not find any association between antibody level and COVID-19 breakthrough infections.
Still, Saxena said the study findings show that vaccination, including a booster shot, provides a meaningful benefit for people with SLE.
“COVID-19 vaccine boosters, or third shots, offered an added, doubled layer of protection from breakthrough infection,” Saxena said. “Even in cases of SARS-CoV-2 infection, cases were overwhelmingly mild among SLE patients who were fully vaccinated.”
Reference
Saxena A, Engel AJ, Banbury B, et al. COVID-19 breakthrough infections, morbidity, and seroreactivity in SLE patients following initial SARS-CoV-2 vaccination series and additional dose through the Omicron BA.1 wave in New York City. Lancet Rheumatol. Pubished online July 12, 2022. doi:10.1016/S2665-9913(22)00190-4
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More